Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT

  • Jan Styczynski
  • Gloria Tridello
  • Lidia Gil
  • Per Ljungman
  • Malgorzata Mikulska
  • Katherine N Ward
  • Catherine Cordonnier
  • Rafael de la Camara
  • Diana Averbuch
  • Nina Knelange
  • Gerard Socié
  • Patrice Chevallier
  • Didier Blaise
  • Ibrahim Yakoub-Agha
  • Edouard Forcade
  • Jan Cornelissen
  • Johan Maertens
  • Eefke Petersen
  • Stéphanie Nguyen-Quoc
  • Hendrik Veelken
  • Nicolaas Schaap
  • Jakob Passweg
  • Mauricette Michallet
  • Nathalie Fegueux
  • Eric Deconinck
  • Nigel Russell
  • Grzegorz Basak
  • Peter Bader
  • Silvia Montoto
  • Nicolaus Kröger
  • Simone Cesaro
  • Infectious Diseases Working Party EBMT


The influence of the donor (D) and recipient (R) pre-transplant Epstein-Barr Virus (EBV) serostatus on transplant outcomes (overall survival, relapse-free survival, relapse incidence, non-relapse mortality, acute and chronic GVHD) in 12,931 patients with lymphomas or chronic malignancies undergoing allogeneic hematopoietic cell transplant (allo-HCT) between 1997-2016 was analyzed. In multivariate analysis, the risk of development of chronic GVHD was increased for EBV R+/D+ (HR = 1.26; p = 0.003), R+/D- (HR = 1.21; p = 0.044), and R-/D + (HR = 1.21; p = 0.048) in comparison to R-/D- transplants. No significance was shown for other transplant outcomes; however, in univariate analysis, EBV-seropositive patients receiving grafts from EBV-seropositive donors (EBV R+/D+transplants) had inferior transplant outcomes in comparison to EBV-seronegative recipients of grafts from EBV-seronegative donors (EBV R-/D-): inferior overall survival (59.6% vs 65.9%), inferior relapse-free survival (51.1% vs 57.5%), increased incidence of chronic GVHD (49.5% vs 41.8%), and increased incidence of de novo chronic GVHD (30.5% vs 24.0%). In conclusion, an EBV-negative recipient with lymphoma or chronic malignancy can benefit from selection of an EBV-negative donor in context of chronic GVHD, while there are no preferences in donor EBV serostatus for EBV-seropositive recipient.

Bibliografische Daten

StatusVeröffentlicht - 12.2019
PubMed 31363166